Soleno Therapeutics Ownership 2024 | Who Owns Soleno Therapeutics Now?

Overview Forecast RevenueFinancials Chart

Institutional Ownership

1.26%

Insider Ownership

4.58%

Retail Ownership

94.16%

Institutional Holders

2.00

Soleno Therapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
TCG CROSSOVER MANAGEMENT, LLC	3.33%	1.86%	550,000	550,000	100.00%	23,540,000	Mar 31, 2024

Soleno Therapeutics's largest institutional shareholder is TCG CROSSOVER MANAGEMENT, LLC, holding 3.33% of the company's total share outstanding, currently valued at $23.54M. The top 10 institutional shareholders own together 3.33% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
TCG CROSSOVER MANAGEMENT, LLC	3.33%	1.86%	550,000	550,000	100.00%	23,540,000	Mar 31, 2024

The largest Soleno Therapeutics shareholder by % of total assets is TCG CROSSOVER MANAGEMENT, LLC. The company owns 550.00K shares of Soleno Therapeutics (SLNO), representing 1.86% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
TCG CROSSOVER MANAGEMENT, LLC	3.33%	1.86%	550,000	550,000	100.00%	23,540,000	Mar 31, 2024

As of Mar 31 2024, Soleno Therapeutics's largest institutional buyer is TCG CROSSOVER MANAGEMENT, LLC. The company purchased 550.00K stocks of SLNO, valued at $23.54M.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
TCG CROSSOVER MANAGEMENT, LLC	3.33%	1.86%	550,000	550,000	100.00%	23,540,000	Mar 31, 2024

As of Mar 31 2024, Soleno Therapeutics's biggest institutional seller is TCG CROSSOVER MANAGEMENT, LLC. The company sold 550.00K shares of SLNO, valued at $23.54M.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
TCG CROSSOVER MANAGEMENT, LLC	3.33%	1.86%	550,000	550,000	100.00%	23,540,000	Mar 31, 2024

Soleno Therapeutics's largest new institutional shareholder by number of shares is TCG CROSSOVER MANAGEMENT, LLC, purchased 550.00K shares, valued at $23.54M, as of undefined.

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date

Soleno Therapeutics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
DEUTSCHE DWS INVESTMENTS VIT FUNDS	0.02%	9,839	-	-	Dec 31, 2023
QUANTITATIVE MASTER SERIES LLC	0.02%	105,332	-	-	Dec 31, 2023
TIAA SEPARATE ACCOUNT VA 1	0.01%	2,198	-	-	Dec 31, 2023
VANGUARD INDEX FUNDS	0.00%	1,950,152	-	-	Dec 31, 2023
SCHWAB CAPITAL TRUST	0.00%	123,492	-	-	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	1,156,596	1,101,645	2004.78%	Dec 31, 2023
VANGUARD INSTITUTIONAL INDEX FUNDS	0.00%	66,304	-	-	Dec 31, 2023
TIAA-CREF LIFE FUNDS	0.00%	5,525	-	-	Dec 31, 2023
FIDELITY CONCORD STREET TRUST	0.00%	402,349	-	-	Feb 29, 2024
ETFis Series Trust I	0.00%	2,207	2,207	-	Jan 31, 2024
FINANCIAL INVESTORS TRUST	0.00%	107,983	-	-	Jan 31, 2024
Calvert Variable Products, Inc.	0.00%	2,954	-	-	Dec 31, 2023
SunAmerica Specialty Series	0.00%	491	-	-	Apr 30, 2021
Voya VARIABLE PORTFOLIOS INC	0.00%	28,835	-	-	Dec 31, 2023
ProFunds	0.00%	5,520	2,612	89.82%	Jan 31, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS	0.00%	14,591	10,170	230.09%	Dec 31, 2023
PENN SERIES FUNDS INC	0.00%	9,467	2,000	26.78%	Dec 29, 2023
ALLSPRING MASTER TRUST	0.00%	15,887	-	-	Feb 29, 2024
FIDELITY SALEM STREET TRUST	0.00%	517,907	-	-	Feb 29, 2024
PGIM ETF TRUST	0.00%	12,512	-	-	Feb 29, 2024
ProFunds	0.00%	1,292	-	-	Jan 31, 2024
HC CAPITAL TRUST	0.00%	3,995	-	-	Dec 31, 2023
STATE STREET INSTITUTIONAL INVESTMENT TRUST	0.00%	11,000	-	-	Dec 31, 2023
VALIC Co I	0.00%	28,273	-	-	Feb 29, 2024
VANGUARD SCOTTSDALE FUNDS	0.00%	189,525	-	-	Feb 29, 2024
PENN SERIES FUNDS INC	0.00%	2,600	-	-	Dec 29, 2023
NATIONWIDE VARIABLE INSURANCE TRUST	0.00%	11,408	-	-	Dec 31, 2023
PACE SELECT ADVISORS TRUST	0.00%	20,106	-	-	Jan 31, 2024
NATIONWIDE MUTUAL FUNDS	0.00%	7,175	-	-	Jan 31, 2024
COLLEGE RETIREMENT EQUITIES FUND	0.00%	42,474	-	-	Dec 31, 2023
NORTHERN FUNDS	0.00%	31,902	-	-	Dec 29, 2023
T. Rowe Price Index Trust, Inc.	0.00%	603	-	-	Feb 29, 2024
MORGAN STANLEY PATHWAY FUNDS	0.00%	2,415	-	-	Feb 29, 2024
SUNAMERICA SERIES TRUST	0.00%	6,442	-	-	Jan 31, 2024
DFA INVESTMENT DIMENSIONS GROUP INC	0.00%	15,466	-	-	Jan 31, 2024
SPDR SERIES TRUST	0.00%	462,912	462,912	-	Dec 31, 2023
Dimensional ETF Trust	0.00%	5,288	-	-	Jan 31, 2024
EQ ADVISORS TRUST	0.00%	11,459	-	-	Dec 31, 2023
SEI INSTITUTIONAL MANAGED TRUST	0.00%	26,578	-6,522	-19.70%	Dec 31, 2023
JOHN HANCOCK VARIABLE INSURANCE TRUST	0.00%	18,275	-	-	Dec 31, 2023
EXCHANGE TRADED CONCEPTS TRUST	0.00%	46	-	-	Feb 29, 2024
PACIFIC SELECT FUND	0.00%	26,716	-	-	Dec 31, 2023
MASSMUTUAL SELECT FUNDS	0.00%	7,093	-	-	Dec 31, 2023
Pacer Funds Trust	0.00%	283	283	-	Jan 31, 2024
ADVANCED SERIES TRUST	0.00%	22,647	-	-	Dec 29, 2023
NATIONWIDE MUTUAL FUNDS	0.00%	631	631	-	Jan 31, 2024
Bridge Builder Trust	0.00%	21,044	-	-	Dec 31, 2023
Advisors' Inner Circle Fund III	0.00%	31	-	-	Jan 31, 2024
BlackRock Variable Series Funds, Inc.	0.00%	7,871	-	-	Dec 31, 2023
PRINCIPAL FUNDS, INC.	0.00%	9,877	-	-	Feb 29, 2024
John Hancock Funds II	0.00%	10,297	-	-	Feb 29, 2024
BLACKROCK FUNDS	0.00%	2,648	-	-	Feb 29, 2024

Soleno Therapeutics's largest mutual fund holder by % of total assets is "DEUTSCHE DWS INVESTMENTS VIT FUNDS", owning 9.84K shares, compromising 0.02% of its total assets.

Soleno Therapeutics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
30 Sep, 22	2	-93.94%
30 Jun, 22	33	-
31 Mar, 22	33	-5.71%
31 Dec, 21	35	-2.78%
30 Sep, 21	36	-26.53%
30 Jun, 21	49	-22.22%
31 Mar, 21	63	-4.55%
31 Dec, 20	66	4.76%
30 Sep, 20	63	-11.27%
30 Jun, 20	71	136.67%
31 Mar, 20	30	66.67%
31 Dec, 19	18	5.88%
30 Sep, 19	17	-5.56%
30 Jun, 19	18	-10.00%
31 Mar, 19	20	25.00%
31 Dec, 18	16	14.29%
30 Sep, 18	14	-12.50%
30 Jun, 18	16	100.00%
31 Mar, 18	8	-
31 Dec, 17	8	-

As of 30 Sep 22, 2 institutions are holding Soleno Therapeutics's shares, representing a decrease of -93.94% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
30 Sep, 22	102,288	-99.77%
30 Jun, 22	45,016,284	-3.96%
31 Mar, 22	46,870,805	68.28%
31 Dec, 21	27,853,132	-1.84%
30 Sep, 21	28,376,288	-0.73%
30 Jun, 21	28,583,907	-9.89%
31 Mar, 21	31,721,894	-24.95%
31 Dec, 20	42,265,256	1.42%
30 Sep, 20	41,674,320	1.74%
30 Jun, 20	40,959,917	99.96%
31 Mar, 20	20,484,002	19.04%
31 Dec, 19	17,207,800	71.02%
30 Sep, 19	10,062,024	-30.11%
30 Jun, 19	14,396,615	-0.01%
31 Mar, 19	14,397,730	-2.74%
31 Dec, 18	14,803,113	67.28%
30 Sep, 18	8,849,455	0.60%
30 Jun, 18	8,796,506	5.09%
31 Mar, 18	8,370,203	1.34%
31 Dec, 17	8,259,274	-

Soleno Therapeutics (SLNO) has 102.29K shares outstanding as of 30 Sep 22, down -99.77% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
30 Sep, 22	1.26%	0.00%
30 Jun, 22	562.29%	0.07%
31 Mar, 22	878.60%	0.32%
31 Dec, 21	523.75%	0.18%
30 Sep, 21	533.45%	0.18%
30 Jun, 21	537.65%	0.15%
31 Mar, 21	597.06%	0.09%
31 Dec, 20	796.37%	0.13%
30 Sep, 20	785.49%	0.04%
30 Jun, 20	1328.83%	0.28%
31 Mar, 20	687.69%	0.17%
31 Dec, 19	627.02%	0.28%
30 Sep, 19	474.72%	0.10%
30 Jun, 19	679.58%	0.15%
31 Mar, 19	680.08%	0.06%
31 Dec, 18	1058.60%	0.28%
30 Sep, 18	619.35%	0.15%
30 Jun, 18	648.54%	0.16%
31 Mar, 18	642.86%	0.16%
31 Dec, 17	634.34%	-

As of 30 Sep 22, Soleno Therapeutics is held by 1.26% institutional shareholders, representing a 0.00% growth compared to 30 Jun 22.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
30 Sep, 22	1	-90.91%
30 Jun, 22	11	-15.38%
31 Mar, 22	13	18.18%
31 Dec, 21	11	-21.43%
30 Sep, 21	14	-30.00%
30 Jun, 21	20	-23.08%
31 Mar, 21	26	-18.75%
31 Dec, 20	32	-13.51%
30 Sep, 20	37	-37.29%
30 Jun, 20	59	210.53%
31 Mar, 20	19	72.73%
31 Dec, 19	11	10.00%
30 Sep, 19	10	25.00%
30 Jun, 19	8	-33.33%
31 Mar, 19	12	50.00%
31 Dec, 18	8	-
30 Sep, 18	8	-42.86%
30 Jun, 18	14	250.00%
31 Mar, 18	4	-50.00%
31 Dec, 17	8	-

1 institutional shareholders have increased their position in SLNO stock as of 30 Sep 22 compared to 11 in the previous quarter (a -90.91% decrease).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
30 Sep, 22	1	-90.00%
30 Jun, 22	10	-
31 Mar, 22	10	66.67%
31 Dec, 21	6	-
30 Sep, 21	6	-66.67%
30 Jun, 21	18	-14.29%
31 Mar, 21	21	5.00%
31 Dec, 20	20	66.67%
30 Sep, 20	12	140.00%
30 Jun, 20	5	25.00%
31 Mar, 20	4	-20.00%
31 Dec, 19	5	66.67%
30 Sep, 19	3	-40.00%
30 Jun, 19	5	66.67%
31 Mar, 19	3	-
31 Dec, 18	3	200.00%
30 Sep, 18	1	-
30 Jun, 18	1	-
31 Mar, 18	1	-
31 Dec, 17	-	-

1 institutional shareholders have reduced their position in SLNO stock as of 30 Sep 22 compared to 10 in the previous quarter (a -90.00% decrease).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
30 Sep, 22	2	-93.94%	102,288	-99.77%	1.26%	0.00%	1	-90.91%	1	-90.00%
30 Jun, 22	33	-	45,016,284	-3.96%	562.29%	0.07%	11	-15.38%	10	-
31 Mar, 22	33	-5.71%	46,870,805	68.28%	878.60%	0.32%	13	18.18%	10	66.67%
31 Dec, 21	35	-2.78%	27,853,132	-1.84%	523.75%	0.18%	11	-21.43%	6	-
30 Sep, 21	36	-26.53%	28,376,288	-0.73%	533.45%	0.18%	14	-30.00%	6	-66.67%
30 Jun, 21	49	-22.22%	28,583,907	-9.89%	537.65%	0.15%	20	-23.08%	18	-14.29%
31 Mar, 21	63	-4.55%	31,721,894	-24.95%	597.06%	0.09%	26	-18.75%	21	5.00%
31 Dec, 20	66	4.76%	42,265,256	1.42%	796.37%	0.13%	32	-13.51%	20	66.67%
30 Sep, 20	63	-11.27%	41,674,320	1.74%	785.49%	0.04%	37	-37.29%	12	140.00%
30 Jun, 20	71	136.67%	40,959,917	99.96%	1328.83%	0.28%	59	210.53%	5	25.00%
31 Mar, 20	30	66.67%	20,484,002	19.04%	687.69%	0.17%	19	72.73%	4	-20.00%
31 Dec, 19	18	5.88%	17,207,800	71.02%	627.02%	0.28%	11	10.00%	5	66.67%
30 Sep, 19	17	-5.56%	10,062,024	-30.11%	474.72%	0.10%	10	25.00%	3	-40.00%
30 Jun, 19	18	-10.00%	14,396,615	-0.01%	679.58%	0.15%	8	-33.33%	5	66.67%
31 Mar, 19	20	25.00%	14,397,730	-2.74%	680.08%	0.06%	12	50.00%	3	-
31 Dec, 18	16	14.29%	14,803,113	67.28%	1058.60%	0.28%	8	-	3	200.00%
30 Sep, 18	14	-12.50%	8,849,455	0.60%	619.35%	0.15%	8	-42.86%	1	-
30 Jun, 18	16	100.00%	8,796,506	5.09%	648.54%	0.16%	14	250.00%	1	-
31 Mar, 18	8	-	8,370,203	1.34%	642.86%	0.16%	4	-50.00%	1	-
31 Dec, 17	8	-	8,259,274	-	634.34%	-	8	-	-	-

Soleno Therapeutics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
May 01, 2024	Vivo Opportunity, LLC	10 percent owner	-	S-Sale	Sell	750,000	$47.80	$35.85M	7,668,093
May 01, 2024	Vivo Opportunity, LLC	10 percent owner	-	S-Sale	Sell	351,242	$45.13	$15.85M	7,316,851
Apr 03, 2024	Yen Kristen	officer	SEE REMARKS	S-Sale	Sell	1,330	$41.12	$54.69K	24,310
Apr 03, 2024	Yen Kristen	officer	SEE REMARKS	S-Sale	Sell	888	$41.67	$37.00K	23,422
Apr 03, 2024	Mackaness James H	officer	CHIEF FINANCIAL OFFICER	S-Sale	Sell	3,104	$41.12	$127.64K	65,024
Apr 03, 2024	Mackaness James H	officer	CHIEF FINANCIAL OFFICER	S-Sale	Sell	2,071	$41.67	$86.29K	62,953
Apr 03, 2024	Hirano Patricia C	officer	SEE REMARKS	S-Sale	Sell	888	$41.67	$37.00K	50,924
Apr 03, 2024	Hirano Patricia C	officer	SEE REMARKS	S-Sale	Sell	1,330	$41.12	$54.69K	41,812
Apr 03, 2024	Anish Bhatnagar	director, officer	CHIEF EXECUTIVE OFFICER	S-Sale	Sell	11,383	$41.12	$468.10K	160,387
Apr 03, 2024	Anish Bhatnagar	director, officer	CHIEF EXECUTIVE OFFICER	S-Sale	Sell	7,597	$41.67	$316.54K	152,790
Jan 29, 2024	Yen Kristen	officer	SEE REMARKS	S-Sale	Sell	397	$48.30	$19.18K	25,640
Jan 29, 2024	Hirano Patricia C	officer	SEE REMARKS	S-Sale	Sell	832	$48.30	$40.19K	43,142
Jan 29, 2024	Anish Bhatnagar	director, officer	CHIEF EXECUTIVE OFFICER	S-Sale	Sell	2,527	$48.30	$122.05K	171,770

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
May 01, 2024	Vivo Opportunity, LLC	10 percent owner	-	S-Sale	Sell	750,000	$47.80	$35.85M	7,668,093
May 01, 2024	Vivo Opportunity, LLC	10 percent owner	-	S-Sale	Sell	351,242	$45.13	$15.85M	7,316,851
Apr 30, 2024	Manning Meredith	officer	Chief Commercial Officer		Sell	128,000	$46.31	$5.93M	-
Apr 30, 2024	Huang Michael F.	officer	Sr. VP of Clinical Development		Sell	120,000	$21.93	$2.63M	-
Apr 03, 2024	Yen Kristen	officer	SEE REMARKS	S-Sale	Sell	1,330	$41.12	$54.69K	24,310
Apr 03, 2024	Yen Kristen	officer	SEE REMARKS	S-Sale	Sell	888	$41.67	$37.00K	23,422
Apr 03, 2024	Mackaness James H	officer	CHIEF FINANCIAL OFFICER	S-Sale	Sell	3,104	$41.12	$127.64K	65,024
Apr 03, 2024	Mackaness James H	officer	CHIEF FINANCIAL OFFICER	S-Sale	Sell	2,071	$41.67	$86.29K	62,953
Apr 03, 2024	Hirano Patricia C	officer	SEE REMARKS	S-Sale	Sell	888	$41.67	$37.00K	50,924
Apr 03, 2024	Hirano Patricia C	officer	SEE REMARKS	S-Sale	Sell	1,330	$41.12	$54.69K	41,812
Apr 03, 2024	Anish Bhatnagar	director, officer	CHIEF EXECUTIVE OFFICER	S-Sale	Sell	11,383	$41.12	$468.10K	160,387
Apr 03, 2024	Anish Bhatnagar	director, officer	CHIEF EXECUTIVE OFFICER	S-Sale	Sell	7,597	$41.67	$316.54K	152,790
Jan 29, 2024	Yen Kristen	officer	SEE REMARKS	S-Sale	Sell	397	$48.30	$19.18K	25,640
Jan 29, 2024	Hirano Patricia C	officer	SEE REMARKS	S-Sale	Sell	832	$48.30	$40.19K	43,142
Jan 29, 2024	Anish Bhatnagar	director, officer	CHIEF EXECUTIVE OFFICER	S-Sale	Sell	2,527	$48.30	$122.05K	171,770
Jan 10, 2024	MARIO ERNEST	director	-	G-Gift	Sell	3,523	-	-	124,566

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
May 01, 2024	Vivo Opportunity, LLC	10 percent owner	-	S-Sale	Sell	750,000	$47.80	$35.85M	7,668,093
May 01, 2024	Vivo Opportunity, LLC	10 percent owner	-	S-Sale	Sell	351,242	$45.13	$15.85M	7,316,851
Apr 30, 2024	Manning Meredith	officer	Chief Commercial Officer		Sell	128,000	$46.31	$5.93M	-
Apr 30, 2024	Huang Michael F.	officer	Sr. VP of Clinical Development		Sell	120,000	$21.93	$2.63M	-
Apr 03, 2024	Yen Kristen	officer	SEE REMARKS	S-Sale	Sell	1,330	$41.12	$54.69K	24,310
Apr 03, 2024	Yen Kristen	officer	SEE REMARKS	S-Sale	Sell	888	$41.67	$37.00K	23,422
Apr 03, 2024	Mackaness James H	officer	CHIEF FINANCIAL OFFICER	S-Sale	Sell	3,104	$41.12	$127.64K	65,024
Apr 03, 2024	Mackaness James H	officer	CHIEF FINANCIAL OFFICER	S-Sale	Sell	2,071	$41.67	$86.29K	62,953
Apr 03, 2024	Hirano Patricia C	officer	SEE REMARKS	S-Sale	Sell	888	$41.67	$37.00K	50,924
Apr 03, 2024	Hirano Patricia C	officer	SEE REMARKS	S-Sale	Sell	1,330	$41.12	$54.69K	41,812
Apr 03, 2024	Anish Bhatnagar	director, officer	CHIEF EXECUTIVE OFFICER	S-Sale	Sell	11,383	$41.12	$468.10K	160,387
Apr 03, 2024	Anish Bhatnagar	director, officer	CHIEF EXECUTIVE OFFICER	S-Sale	Sell	7,597	$41.67	$316.54K	152,790
Jan 29, 2024	Yen Kristen	officer	SEE REMARKS	S-Sale	Sell	397	$48.30	$19.18K	25,640
Jan 29, 2024	Hirano Patricia C	officer	SEE REMARKS	S-Sale	Sell	832	$48.30	$40.19K	43,142
Jan 29, 2024	Anish Bhatnagar	director, officer	CHIEF EXECUTIVE OFFICER	S-Sale	Sell	2,527	$48.30	$122.05K	171,770
Jan 10, 2024	MARIO ERNEST	director	-	G-Gift	Sell	3,523	-	-	124,566
Jan 08, 2024	Yen Kristen	officer	See Remarks	A-Award	Buy	24,000	-	-	26,037
Jan 08, 2024	Yen Kristen	officer	See Remarks	A-Award	Buy	16,000	$36.70	$587.20K	16,000
Jan 08, 2024	Mackaness James H	officer	Chief Financial Officer	A-Award	Buy	56,000	-	-	68,128
Jan 08, 2024	Mackaness James H	officer	Chief Financial Officer	A-Award	Buy	37,000	$36.70	$1.36M	37,000

The last insider sell of Soleno Therapeutics's stock was made by Vivo Opportunity, LLC on May 01 2024, selling 750,000 shares at $47.80 per share (valued at $35.85M).

Soleno Therapeutics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q2 2024	-	12	-
Q1 2024	8	4	200.00%
Q4 2023	10	42	23.81%
Q3 2023	20	2	1000.00%
Q2 2023	36	-	-
Q1 2023	4	-	-
Q4 2022	-	31	-
Q3 2022	7	18	38.89%
Q2 2022	5	-	-
Q1 2022	22	3	733.33%
Q4 2021	3	1	300.00%
Q3 2021	4	5	80.00%
Q2 2021	11	7	157.14%
Q1 2021	12	22	54.55%
Q4 2020	4	6	66.67%
Q3 2020	4	-	-
Q2 2020	19	2	950.00%
Q1 2020	8	-	-
Q4 2019	5	18	27.78%
Q3 2019	2	-	-

0 total buy trades, and 12 total sell trades (buy/sell ratio of 0.00%) were made by Soleno Therapeutics's insiders, as of Q2 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q2 2024	-	10	-
Q1 2024	-	3	-
Q4 2023	-	31	-
Q3 2023	16	-	-
Q2 2023	14	-	-
Q1 2023	-	-	-
Q4 2022	-	31	-
Q3 2022	-	18	-
Q2 2022	-	-	-
Q1 2022	15	2	750.00%
Q4 2021	-	-	-
Q3 2021	1	4	25.00%
Q2 2021	-	6	-
Q1 2021	-	15	-
Q4 2020	-	6	-
Q3 2020	-	-	-
Q2 2020	6	2	300.00%
Q1 2020	-	-	-
Q4 2019	5	18	27.78%
Q3 2019	2	-	-

As of Q2 2024, Insider owners conducted 0 open market buy trades and 10 open market sell trades of Soleno Therapeutics's stocks.

Soleno Therapeutics Peer Ownership

Ticker	Company
ABOS	Acumen Pharmaceuticals, Inc.
MBRX	Moleculin Biotech, Inc.
CAPR	Capricor Therapeutics, Inc.
ALRN	Aileron Therapeutics, Inc.
VECT	VectivBio Holding AG
XFOR	X4 Pharmaceuticals, Inc.
INZY	Inozyme Pharma, Inc.
DAWN	Day One Biopharmaceuticals, Inc.
DFFN	CervoMed Inc.
ANNX	Annexon, Inc.
BPTH	Bio-Path Holdings, Inc.
PULM	Pulmatrix, Inc.
AKTX	Akari Therapeutics, Plc
BOLT	Bolt Biotherapeutics, Inc.
ONTX	Traws Pharma, Inc.
LYRA	Lyra Therapeutics, Inc.
CBIO	Gyre Therapeutics, Inc.
BNTC	Benitec Biopharma Inc.

SLNO Ownership FAQ

Who Owns Soleno Therapeutics?

Soleno Therapeutics is owned by institutional shareholders (1.26%), insiders (4.58%), and public (94.16%). The largest institutional shareholder of Soleno Therapeutics is TCG CROSSOVER MANAGEMENT, LLC (3.33% of total shares) and the top mutual fund owner is DEUTSCHE DWS INVESTMENTS VIT FUNDS (0.02% of total shares).

Who are the major institutional shareholders of Soleno Therapeutics?

Soleno Therapeutics's major institutional shareholders are TCG CROSSOVER MANAGEMENT, LLC. The top five shareholders own together 3.33% of the company's share outstanding.

How many Soleno Therapeutics shareholders are there?

As of Sep 2022, there are 2 institutional shareholders of Soleno Therapeutics.

What percentage of Soleno Therapeutics is owned by TCG CROSSOVER MANAGEMENT, LLC?

TCG CROSSOVER MANAGEMENT, LLC owns 550K shares of Soleno Therapeutics, representing 3.33% of the company's total shares outstanding, valued at $23.54M (as of Mar 2024).